Sign up to save your podcasts
Or
Share SABCS 2024 Highlights - DESTINY-Breast06, DESTINY-Breast12, PATINA with Dr. Sara Tolaney
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
SABCS 2024 Highlights - DESTINY-Breast06, DESTINY-Breast12, PATINA with Dr. Sara Tolaney
Join us for another insightful episode of the Oncology Brothers podcast as we dive into the latest breakthroughs in breast cancer research from the San Antonio Breast Cancer Symposium 2024. In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Sara Tolaney from Dana-Farber Cancer Institute to discuss three pivotal studies:
1. DESTINY-Breast06 - An update on the efficacy of T-DXd in HER2 low and ultra-low breast cancer patients, highlighting its potential to change treatment paradigms for endocrine refractory disease.
2. DESTINY-Breast12 - Exploring the robust intracranial activity of T-DXd in patients with brain metastases and its impact on quality of life.
3. PATINA Trial - A groundbreaking study on the use of CDK4-6 inhibitors in combination with trastuzumab and pertuzumab for ER-positive, HER2-positive breast cancer, showcasing impressive progression-free survival rates.
Tune in as we unpack the implications of these studies for clinical practice and discuss the future of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates on oncology research and treatment strategies!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
For more information, visit our website: OncologyBrothers.com
#OncologyBrothers #BreastCancer #SABCS2024 #TDXD #PATINA #CancerResearch #Podcast
View all episodes
By Oncology Brothers
4.8
4040 ratings
Join us for another insightful episode of the Oncology Brothers podcast as we dive into the latest breakthroughs in breast cancer research from the San Antonio Breast Cancer Symposium 2024. In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Sara Tolaney from Dana-Farber Cancer Institute to discuss three pivotal studies:
1. DESTINY-Breast06 - An update on the efficacy of T-DXd in HER2 low and ultra-low breast cancer patients, highlighting its potential to change treatment paradigms for endocrine refractory disease.
2. DESTINY-Breast12 - Exploring the robust intracranial activity of T-DXd in patients with brain metastases and its impact on quality of life.
3. PATINA Trial - A groundbreaking study on the use of CDK4-6 inhibitors in combination with trastuzumab and pertuzumab for ER-positive, HER2-positive breast cancer, showcasing impressive progression-free survival rates.
Tune in as we unpack the implications of these studies for clinical practice and discuss the future of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates on oncology research and treatment strategies!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
For more information, visit our website: OncologyBrothers.com
#OncologyBrothers #BreastCancer #SABCS2024 #TDXD #PATINA #CancerResearch #Podcast
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
318 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
115 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
290 Listeners
White Coat Investor Podcast
2,442 Listeners
The Curbsiders Internal Medicine Podcast
3,339 Listeners
Core IM | Internal Medicine Podcast
1,151 Listeners
The ONS Podcast
196 Listeners
OncoPharm
185 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
22 Listeners
Becker’s Healthcare Podcast
191 Listeners
Oncology Today with Dr Neil Love
57 Listeners
Two Onc Docs
189 Listeners